Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17967299 | 1.00 | KMT2A (0.55) | KMT2ATSHRMAPK1LMNATP53 | |
| SCHEMBL17967267 | 1.00 | KMT2A (0.55) | KMT2ATSHRMAPK1LMNATP53 | |
| SCHEMBL3367168 | 0.90 | LMNA (0.52) | LMNATP53POLBMAPTKDM4E | |
| SCHEMBL3367166 | 0.90 | LMNA (0.52) | LMNATP53POLBMAPTKDM4E | |
| SCHEMBL16491302 | 0.89 | LMNA (0.51) | LMNATP53POLBMAPTKDM4E | |
| SCHEMBL16491301 | 0.89 | LMNA (0.51) | LMNATP53POLBMAPTKDM4E | |
| SCHEMBL12841501 | 0.89 | TP53 (0.58) | KMT2ALMNATP53POLBMAPT | |
| SCHEMBL16491304 | 0.89 | LMNA (0.51) | LMNATP53POLBMAPTKDM4E | |
| SCHEMBL17383722 | 0.88 | POLB (0.61) | KMT2ALMNATP53POLBMAPT | |
| SCHEMBL17967145 | 0.85 | POLB (0.49) | LMNATP53POLBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107428736-B | Home chemokine inhibitors | 癌症研究科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| CN-107428736-A | Oneself chemotactic element inhibitor | 癌症研究科技有限公司 | 2017-12-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | ENPP2, RNASE1, ATXN10 | KMT2A 353/4885TSHR 1495/4885MAPK1 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.